GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (NAS:ATHE) » Definitions » 10-Year RORE %

Alterity Therapeutics (Alterity Therapeutics) 10-Year RORE % : 0.00% (As of Sep. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Alterity Therapeutics 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Alterity Therapeutics's 10-Year RORE % for the quarter that ended in Sep. 2023 was 0.00%.

The industry rank for Alterity Therapeutics's 10-Year RORE % or its related term are showing as below:

ATHE's 10-Year RORE % is not ranked *
in the Biotechnology industry.
Industry Median: -5.095
* Ranked among companies with meaningful 10-Year RORE % only.

Alterity Therapeutics 10-Year RORE % Historical Data

The historical data trend for Alterity Therapeutics's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alterity Therapeutics 10-Year RORE % Chart

Alterity Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.86 -3.25 -2.65 -5.26 -7.51

Alterity Therapeutics Quarterly Data
Dec17 Jun18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.65 - -7.51 - -

Competitive Comparison of Alterity Therapeutics's 10-Year RORE %

For the Biotechnology subindustry, Alterity Therapeutics's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alterity Therapeutics's 10-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's 10-Year RORE % falls into.



Alterity Therapeutics 10-Year RORE % Calculation

Alterity Therapeutics's 10-Year RORE % for the quarter that ended in Sep. 2023 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( -0.966--7.693 )/( -179.105-0 )
=6.727/-179.105
=-3.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2023 and 10-year before.


Alterity Therapeutics  (NAS:ATHE) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Alterity Therapeutics 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Alterity Therapeutics's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alterity Therapeutics (Alterity Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Collins Street, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.